

Document Title: **Annual Report WPA section on Personalized Psychiatry**
Document Type: Annual Report 2025
Author: Giampaolo Robert Perna
Date Created: 17 March 2026



2025 Annual Report WPA section on Personalized Psychiatry

Members List:

Ned Kalin USA nkalin@wisc.edu
Daniela Caldirola Italy daniela.caldirola@hunimed.eu
Massimiliano Grassi Italy massi.gra@gmail.com
Paolo Cavedini Italy p.cavedini@ospedaliere.it
Paolo Girardi Italy paolo.girardi@uniroma1.it
Amit Etkin USA amitetkin@stanford.edu
Jordan Smoller USA jsmoller@hms.harvard.edu
Radu Saveanu USA RSaveanu@med.miami.edu
Philip Harvey USA PHarvey@med.miami.edu
Elisabeth Binder Germany binder@mpipsykl.mpg.de
Madhukar Trivedi USA madhukar.trivedi@utsouthwestern.edu
Richard Shelton USA rshelton@uab.edu
Antonio Egidio Nardi Brazil antonioenardi@gmail.com
Rafael Freire Canada Rafael.ChristophedaRochaFreire@kingstonhsc.ca
Koen Schruers The Netherlands koen.schruers@maastrichtuniversity.nl
Carmine M Pariante UK carmine.pariante@kcl.ac.uk
Francisco del Olmo Spain FDelOlmo@hospitalariasmadrid.org
Manuel Martin Carrasco Spain martincarrasco.manuel@gmail.com
Rene Hurlermann Germany rene.hurlermann@uol.de
Tunk Alkin Turkey tunk.alkin@deu.edu.tr
Joseph Zohar Israel joseph.zohar@sheba.health.gov.il
Bernard Lerer Israel lerer@hadassah.org.il
Jean Pierre Lepine France Jean-pierre.lepine@lrb.aphp.fr
Keith Kendrick China k.kendrick.uestc@gmail.com
James Kennedy Canada jim.kennedy@camh.ca
Francesco Cuniberti Italy francesco.cuniberti@hunimed.eu

Scientific Section Committee and Officers (Elections held in 2023 by email ballott that will be renewed by december 2026))

Section Officers

Chair: Giampaolo Robert Perna (Italy)
Co-Chair: Charles Nemeroff (USA)
Secretary : Alan Schatzberg (USA)

Section Committee Members

Elisabeth Binder (Germany)
Ned Kalin (USA)
Antonio Egidio Nardi (Brazil)
Carmine Pariante (UK)
Koen Schruers (The Netherlands)

Activities of the Section and its members;

With the aim of developing both education among psychiatrist and scientific exchange among researchers we builded a new scientific journal with Elsevier in 2016. After a huge effort the journal “**Personalized Medicine in Psychiatry**” is available and the first Impact factor (JCR) will be released this year (2026). The journal has published 66 scientific papers from all over the world in 2024-2026 . Issue are available (<http://www.personalizedmedpsych.com/current>) with Giampaolo Perna (Chair of the section) and Charles Nemeroff (Co-Chair of the section) and Co-Editors in Chief.

Collaborations aim at research and developing personalized psychiatry tools has been established between the department of Section Chair Giampaolo Perna (including the two other Section members, Daniela Caldirola and Massimiliano Grassi) and both Maastricht University (member of the Section committee: Koen Schruers) and Austin University of Texas at Austin (Section co-chair: Charles Nemeroff).

Publication of the Section, co-authored by its members (a selection 2024-2026);

McIntyre RS, Nemeroff CB, Rasgon N. Implementing artificial intelligence (AI) to facilitate health outcomes in mood disorders: Application versus aspiration. *J Affect Disord.* 2026 Jun 15; 403:121444

Carta MG, Nardi AE. Psychosomatics at the threshold: cancer, mood disorders, and the mental pain of death - where precision medicine meets spirituality. *Front Psychiatry.* 2026 Feb 10;17:1751310.

Mathias NAO, Rodrigues FP, de Brito LGC, Nardi AE. Artificial intelligence for depression: early detection and personalized treatment. *Braz J Psychiatry.* 2026 Jan 7.

Li Z, Trapp NT, Bruss J, Liu X, Wu K, Chen Z, Etkin A, Howard MA, Boes AD, Jiang J. Multimodal evidence for hippocampal engagement and modulation by functional connectivity-guided parietal TMS. *Nat Commun.* 2026 Mar 8.

LoParo D, Dunlop BW, Nemeroff CB, Mayberg HS, Craighead WE. Prediction of individual patient outcomes to psychotherapy vs medication for major depression. *Npj Ment Health Res.* 2025 Feb 5;4(1):4.

Wang G, Aguado M, Spear MA, Alphs L, Chen C, Huang H, Lu XX, Doostzadeh J, Wu S, Wang S, Patel A, Nemeroff CB, Wang Z, Li A, Luo W. ANK3 as a Novel Genetic Biomarker for Liafensine in Treatment-Resistant Depression: The ENLIGHTEN Randomized Clinical Trial. *JAMA Psychiatry.* 2025 Dec 1;82(12):1186-1194.

Sforzini L, Marizzoni M, Bottanelli C, Kunšteková V, Zonca V, Saleri S, Kose M, Lombardo G, Mariani N, Nettis MA, Nikkheslat N, Worrell C, Zajkowska Z, Pointon L, Cowen PJ, Cavanagh J, Harrison NA, Riva MA, Mondelli V, Bullmore ET; Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA) Consortium; Cattaneo A, Pariante CM. Transcriptomic profiles in major depressive disorder: the role of immunometabolic and cell-cycle-related pathways in

depression with different levels of inflammation. *Mol Psychiatry*. 2025 Apr;30(4):1308-1318

Liu Q, Lai H, Le J, Lan C, Zhang X, Huang L, Xu D, Jiang X, Li F, Kendrick KM, Zhao W. Identifying brain functional subtypes and corresponding task performance profiles in autism spectrum disorder. *Mol Psychiatry*. 2025 Nov;30(11):5034-5044

Zhu H, Tong X, Carlisle NB, Xie H, Keller CJ, Oathes DJ, Liu F, Nemeroff CB, Fonzos GA, Zhang Y. Contrastive functional connectivity defines neurophysiology-informed symptom dimensions in major depression. *Cell Rep Med*. 2025 Jun 17;6(6):102151

Hack LM, Jubeir J, Hilton R, Tozzi L, Boyar L, Zhang X, Lyons T, Jo B, O'Hara R, Schatzberg AF, Williams LM. A stratified precision medicine trial targeting α_{2A} -adrenergic receptor agonism as a treatment for the cognitive biotype of depression. *Nat Ment Health*. 2025;3(11):1363-1373.

Kas MJH, Hyman S, Williams LM, Hidalgo-Mazzei D, Huys QJM, Hotopf M, Cuthbert B, Lewis CM, De Picker LJ, Lalouis PA, Etkin A, Modinos G, Marston HM. Towards a consensus roadmap for a new diagnostic framework for mental disorders. *Eur Neuropsychopharmacol*. 2025 Jan; 90: 16-27.

Pozuelo JR, Lahiri A, Singh RSP, Kushwah A, Khanduri M, Shukla A, Khan A, G S, Shende V, Parashar Y, Mehra YK, Bhan A, Kessler RC, Singla DR, Naslund JA, Choi KW, Cuijpers P, DeRubeis R, Herzallah MM, Lu C, Smoller JW, VanderWeele TJ, Rozatkar AR, Modak T, Joel MM, Biswas D, Atal S, Kulsum U, Hollon SD, Patel V. Optimizing treatment for depression in primary care using psychotherapy versus antidepressant medication in a low-resource setting: protocol for the Optimized randomized controlled trial. *BMC Psychiatry*. 2025 Jul 30;25(1):744

Bigdeli TB, Harvey PD. Recent Advances in Schizophrenia Genomics and Emerging Clinical Implications. *Psychiatr Clin North Am*. 2025 Jun;48(2):311-330.

Miller AH, Berk M, Bloch G, Briquet-Laugier V, Brouillon C, Cuthbert BN, Dantzer R, Davis MC, De Picker LJ, Drevets WC, Eyre HA, Hack LM, Harrison NA, Krystal AD, Lombardo G, Mondelli V, Pariante CM, Pulvirenti L, Salvatore G, Sforzini L, Swieboda P, Trivedi MH, Leboyer M. Advancing precision psychiatry and targeted treatments: Insights from immunopsychiatry. *Brain Behav Immun*. 2025 Mar;125:319-329.

Green M, Trivedi MH, Foster JA. Microbes and mood: innovative biomarker approaches in depression. *Trends Mol Med*. 2025 Jan;31(1):50-63.

Domschke K, Schiele MA, Crespo Salvador Ó, Zillich L, Lipovsek J, Pittig A, Heinig I, Ridderbusch IC, Straube B, Richter J, Hollandt M, Plag J, Fydrich T, Koelkebeck K, Weber H, Lueken U, Dannlowski U, Margraf J, Schneider S, Binder EB, Ströhle A, Rief W, Kircher T, Pauli P, Hamm A, Arolt V, Hoyer J, Wittchen HU, Erhardt-Lehmann A, Köttgen A, Schlosser P, Deckert J. Epigenetic markers of disease risk and psychotherapy response in anxiety disorders - a longitudinal analysis of the DNA methylome. *Mol Psychiatry*. 2025 Oct;30(10):4529-4542.

Brown LC, Zai G, Kennedy JL, Müller DJ, Tavakoli E, Bousman C, Maruf AA. Psychiatric Pharmacogenomic Testing: A Primer for Clinicians. *Psychiatr Clin North Am*. 2025 Jun;48(2):257-264

Walsh CG, Ripperger MA, Hu Y, Sheu YH, Lee H, Wilimitis D, Zheutlin AB, Rocha D, Choi KW, Castro VM, Kirchner HL, Chabris CF, Davis LK, Smoller JW. Development and multi-site external validation of a generalizable risk prediction model for bipolar disorder. *Transl Psychiatry*. 2024 Jan 25;14(1):58.

Curtiss J, Smoller JW, Pedrelli P. Optimizing precision medicine for second-step depression treatment: a machine learning approach. *Psychol Med*. 2024 Jul;54(10):2361-2368

Etkin A, Mathalon DH. Bringing Imaging Biomarkers into Clinical Reality in Psychiatry. *JAMA Psychiatry*. 2024 Nov 1;81(11):1142-1147.

Perna G, Caldirola D, Schatzberg AF, Nemeroff CB. Advancements, challenges and future horizons in personalized psychiatry. *World Psychiatry*. 2024 Oct;23(3):460-461

Perna G, Pinto E, Spiti A, Torti T, Cucchi M, Caldirola D. Foundations for a Personalized Psycho-Oncology: The State of the Art. *J Pers Med*. 2024 Aug 23;14(9):892.

Perna G, Spiti A, Torti T, Daccò S, Caldirola D. Biomarker-Guided Tailored Therapy in Major Depression. *Adv Exp Med Biol*. 2024; 1456:379-400.

Baldi S, Schuhmann T, Goossens L, Schruers KRJ. Individualized, connectome-based, non-invasive stimulation of OCD deep-brain targets: A proof-of-concept. *Neuroimage*. 2024 Mar; 288: 120527.

Tong X, Xie H, Wu W, Keller CJ, Fonzo GA, Chidharom M, Carlisle NB, Etkin A, Zhang Y. Individual deviations from normative electroencephalographic connectivity predict antidepressant response. *J Affect Disord*. 2024 Apr 15; 351: 220-230.

Pallanti S, Zohar J, Kasper S, Möller HJ, Hollander E. Revisiting benzodiazepines (GABA Enhancers): A transdiagnostic and precision medicine approach. *J Psychiatr Res*. 2024 Feb;170:65-72

Tian W, Zhao D, Ding J, Zhan S, Zhang Y, Etkin A, Wu W, Yuan TF. An electroencephalographic signature predicts craving for methamphetamine. *Cell Rep Med*. 2024 Jan 16;5(1):101347.

Action plan 2025-2027

ACTIVITY 1:

Promoting the development of personalized medicine in psychiatry through the promotion of the Elsevier journal "Personalized Medicine in Psychiatry".

ACTIONS: The journal has published 36 scientific papers from all over the world in 2024-2026 (march) and will be indexed in the Journal of Citation Reports (JCR) receiving its first Impact Factor in 2026.

ACTIVITY 2:

Creating a network between psychiatrists interested in the field to potentiate scientific and clinical activities related to personalized psychiatry. Promoting and conducting of international collaborative research projects.

ACTIONS: Several members (Perna G, Caldirola D, Schatzberg AF, Nemeroff CB, Pariante C, Trivedi M) co-authored papers related to the field of personalized psychiatry.

ACTIVITY 3:

Developing themes for intersectional collaboration and starting some joint intersectional projects.

ACTIONS: To be developed

ACTIVITY 4:

Organizing sessions at WPA meeting and other scientific meeting on personalized psychiatry

ACTIONS: Several symposium and lectures by members of the sections and related to Personalized Psychiatry have been included in well known scientific meeting with relevant participation of colleagues:

- AFSP Annual Leadership Conference 2025
- Society of Biological Psychiatry Annual Meeting, 2025, Toronto (Canada)
- 5th Annual Conference on Precision Psychiatry, 2025, USA
- APA's Annual Meeting 2025, Los Angeles, USA
- APA's Annual Meeting 2026, San Francisco, USA

ACTIVITY 5

A. Contribution to the journal World Psychiatry

ACTIONS: Members contributed with several papers official WPA journal:

Correll CU, Cortese S, Solmi M, Boldrini T, Demyttenaere K, Domschke K, Fusar-Poli P, Gorwood P, Harvey PD, Keefe RSE, Knaevelsrud C, Kotov R, Nohr L, Rhee TG, Roe D, Rose M, Schneider LS, Slade M, Stein DJ, Sunkel C, McIntyre RS. Beyond symptom improvement: transdiagnostic and disorder-specific ways to assess functional and quality of life outcomes across mental disorders in adults. *World Psychiatry*. 2025 Oct;24(3):296-318.

Kratter IH, Austelle CW, Lissemore JI, Wada M, Geoly A, Chaiken A, Kaloiani I, Johnson N, Wan S, Kozyr L, Makarewycz E, Wong B, Sridhar M, Espil FM, Bassano N, Kim B, Ehrie J, Maron-Katz A, Tischler C, Nejad R, Batail JM, Phillips AL, Cole EJ, Ford TJ, Bentzley BS, Jo B, Schatzberg AF, Spiegel D, Rolle C, Sahlem GL, Williams NR. Stanford neuromodulation therapy for treatment-resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy. *World Psychiatry*. 2026 Feb;25(1):105-116.